Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen

European Journal of Cancer

Volumn 48, Issue 8, 2012, Pages 1141-1146

  Edeline, Julien ^a,b   Loriot, Yohann ^a   Culine, Stephane ^c   Massard, Christophe ^a   Albiges, Laurence ^a   Blesius, Aurore ^a   Escudier, Bernard ^a   Fizazi, Karim ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE EUGÈNE MARQUIS   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

Chemotherapy; Cisplatin; Gemcitabine; MVAC; Transitional cell carcinoma

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PLATINUM; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CATHETER INFECTION; CLINICAL ARTICLE; DEHYDRATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SEPTIC SHOCK; SIDE EFFECT; SUDDEN DEATH; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 84860443131     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.01.022     Document Type: Article

References (30)

1. Audenet F, Yates DR, Cussenot O, Roupret M. The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). Urol Oncol 2010, in press.
2. C.N. Sternberg, A. Yagoda, and H.I. Scher M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium J Urol 139 1988 461 469
3. C.J. Logothetis, F.H. Dexeus, and L. Finn A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors J Clin Oncol 8 1990 1050 1055
4. H. von der Maase, S.W. Hansen, and J.T. Roberts Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068 3077
5. S. Culine, C. Theodore, and M. De Santis A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen Br J Cancer 94 2006 1395 1401
6. J. Bellmunt, C. Theodore, and T. Demkov Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract J Clin Oncol 27 2009 4454 4461
7. C.N. Sternberg, P.H. de Mulder, and J.H. Schornagel Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924 J Clin Oncol 19 2001 2638 2646
8. C.N. Sternberg, P. de Mulder, and J.H. Schornagel Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours Eur J Cancer 42 2006 50 54
9. G. Sonpavde, C.N. Sternberg, and J.E. Rosenberg Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium Lancet Oncol 11 2010 861 870
10. C.J. Sweeney, B.J. Roth, and F.F. Kabbinavar Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium J Clin Oncol 24 2006 3451 3457
11. J.A. McCaffrey, S. Hilton, and M. Mazumdar Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma J Clin Oncol 15 1997 1853 1857
12. V. Lorusso, C.F. Pollera, and M. Antimi A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer Eur J Cancer 34 1998 1208 1212
13. D. Papamichael, C.J. Gallagher, R.T. Oliver, P.W. Johnson, and J. Waxman Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter Br J Cancer 75 1997 606 607
14. C. Wulfing, J.P. Machiels, and D.J. Richel A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma Cancer 115 2009 2881 2890
15. C. Theodore, L. Geoffrois, and J.B. Vermorken Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers Eur J Cancer 41 2005 1150 1157
16. S. Srinivas, and L.C. Harshman A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma Chemotherapy 55 2009 321 326
17. P. Albers, S.I. Park, and G. Niegisch Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99] Ann Oncol 22 2010 288 294
18. F. Joly, N. Houede, and S. Noal Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study Clin Genitourin Cancer 7 2009 E28 E33
19. K. Kanai, E. Kikuchi, and T. Ohigashi Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy Int J Clin Oncol 13 2008 510 514
20. D.J. Vaughn, C.M. Broome, M. Hussain, J.C. Gutheil, and A.B. Markowitz Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer J Clin Oncol 20 2002 937 940
21. T.M. Beer, B. Goldman, and C.R. Nichols Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy Clin Genitourin Cancer 6 2008 36 39
22. R. Dreicer, S. Li, and J. Manola Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group Cancer 110 2007 759 763
23. R. Dreicer, H. Li, and M. Stein Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group Cancer 115 2009 4090 4095
24. Choueiri TK. A double-blind randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated advanced urothelial cancer. ASCO-GU 2011. [abstract LBA239].
25. Sridhar S. Results of a phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma (UC). ASCO-GU 2011. [abstract 241].
26. C. Theodore, F. Bidault, and N. Bouvet-Forteau A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract Ann Oncol 17 2006 990 994
27. S. Culine, X. Rebillard, and F. Iborra Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: a pilot study Anticancer Res 23 2003 1903 1906
28. S. Culine Chemotherapy for advanced transitional cell carcinoma of the urothelium: cisplatin or carboplatin? Eur Urol 52 2007 9 10
29. L. Dogliotti, G. Carteni, and S. Siena Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial Eur Urol 52 2007 134 141
30. J. Bellmunt, A. Ribas, and N. Eres Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma Cancer 80 10 1997 1966 1972